Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 9/20 | 0.36 |
| ▸ | CSF1R | P07333 | 3/20 | 0.36 |
| ▸ | PAK3 | O75914 | 2/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.36 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.36 |
| ▸ | CCND1 | P24385 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15036384 | 0.87 | PAK4 (0.39) | PKN1PTK2PAK4JAK3MAP4K1 | |
| SCHEMBL15259464 | 0.87 | TLR7 (0.36) | — | |
| SCHEMBL15258233 | 0.82 | PTK2 (0.45) | PKN1PTK2PAK4JAK3CSF1R | |
| SCHEMBL15041735 | 0.80 | CDK4 (0.39) | PKN1PTK2PAK4JAK3CSF1R | |
| SCHEMBL15617448 | 0.80 | PKN1 (0.39) | PKN1PTK2PAK4JAK3MAP4K1 | |
| SCHEMBL15259470 | 0.79 | FGFR1 (0.37) | PKN1PAK4JAK3MAP4K1CSF1R | |
| SCHEMBL15041895 | 0.77 | FGFR1 (0.36) | PKN1PTK2PAK4JAK3MAP4K1 | |
| SCHEMBL15618047 | 0.77 | CCNE1 (0.36) | PKN1PAK4JAK3CSF1RPAK3 | |
| SCHEMBL15041729 | 0.76 | CDK4 (0.46) | PKN1PAK4MAP4K1CSF1RFGFR1 | |
| SCHEMBL15617439 | 0.76 | CDK4 (0.37) | PKN1PTK2PAK4FGFR1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680099-B2 | 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680099-B2 | 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PKN1 326/4885PTK2 12/4885PAK4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.